Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide long-term extension in genetic obesity due to MC4R-pathway defects
NL-OMON54784Phase 3Recruiting
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Sep 2019
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of setmelanotide in Melanocortin-4 receptor pathway disorder (MC4RPD) and obesity, sponsored by Rhythm Pharmaceuticals. Primary endpoint: Safety and tolerability of setmelanotide. Started Sep 2019; status: recruiting.
02
Drugs
setmelanotide
03
Conditions
Melanocortin-4 receptor pathway disorder (MC4RPD)obesity
Beyond the preview
Go deeper on NL-OMON54784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54784.